BIOMAT Database Logo BIOMAT Database Logo

Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia. 1998

C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Department of Cardiology of the University of Athens, Hippokration Hospital, Greece.

Data regarding the effects of plasma lipid lowering on the evolution of thoracic aortic atherosclerosis (TAA) are scarce. In this study, we performed transesophageal echocardiography to characterize TAA in 16 newly diagnosed patients with heterozygous familial hypercholesterolemia and to follow its evolution after 2 years of statin treatment. TAA was graded as follows: grade I = normal intima; grade II = increased intimal echo density without thickening; grade IIIA = increased intimal echo density with single atheromatous plaque < or = 3 mm; grade IIIB = multiple plaques < or = 3mm; grade IV = > or = 1 plaque >3 mm; and grade V = mobile or ulcerated plaques. Baseline aortic intimal morphology was grade I in one patient, grade II in 4, grade IIIA in 6, grade IIIB in 3, and grade IV in 2 patients. Hypolipidemic treatment resulted in significant reductions in plasma total cholesterol and low-density lipoprotein (LDL) cholesterol. Follow-up aortic morphology was grade I in 5 patients, grade II in 2, grade IIIA in 3, grade IIIB in 3, and grade IV in 3 patients. TAA remained stable in 7 patients, progressed in 3, and regressed in 6 patients. TAA evolved in a uniform manner in the ascending aorta, aortic arch, and descending aorta. Patients with TAA regression were younger (39+/-14 vs 52+/-8 years, p=0.038) and had a greater decrease in plasma LDL cholesterol as a result of treatment (138+/-56 vs 73+/-55 mg/dl, p=0.036) than patients with TAA stability or progression. These observations support the hypothesis that hypolipidemic treatment may favorably affect the course of TAA in patients with heterozygous familial hypercholesterolemia.

UI MeSH Term Description Entries
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
[Protective effects of pravastatin against atherosclerosis in children with familial hypercholesterolemia].
March 2005, Revue medicale suisse,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Aortic stiffness in young patients with heterozygous familial hypercholesterolemia.
April 1998, American heart journal,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Development of coronary atherosclerosis in asymptomatic heterozygous patients with familial hypercholesterolemia.
August 1996, Journal of cardiology,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia.
January 2016, PloS one,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia.
December 1993, The Tokai journal of experimental and clinical medicine,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
MR virtual angioscopy of thoracic aortic atherosclerosis in homozygous familial hypercholesterolemia.
January 2001, Journal of computer assisted tomography,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy.
February 2006, The Journal of pediatrics,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
December 1984, The Journal of clinical investigation,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).
February 2002, Journal of the American College of Cardiology,
C E Pitsavos, and K I Aggeli, and J D Barbetseas, and I N Skoumas, and S G Lambrou, and A A Frogoudaki, and C I Stefanadis, and P K Toutouzas
Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia.
April 2010, Paediatric drugs,
Copied contents to your clipboard!